Machine Learning Applied to the Modeling of Pharmacological and ADMET Endpoints.

Journal: Methods in molecular biology (Clifton, N.J.)
Published Date:

Abstract

The well-known concept of quantitative structure-activity relationships (QSAR) has been gaining significant interest in the recent years. Data, descriptors, and algorithms are the main pillars to build useful models that support more efficient drug discovery processes with in silico methods. Significant advances in all three areas are the reason for the regained interest in these models. In this book chapter we review various machine learning (ML) approaches that make use of measured in vitro/in vivo data of many compounds. We put these in context with other digital drug discovery methods and present some application examples.

Authors

  • Andreas H Göller
    Bayer AG, Pharmaceuticals, R&D, Computational Molecular Design, 42096 Wuppertal, Germany.
  • Lara Kuhnke
    Bayer HealthCare, Berlin, Germany.
  • Antonius Ter Laak
    Bayer AG, Pharmaceuticals, R&D, Computational Molecular Design, 13342 Berlin, Germany.
  • Katharina Meier
    Pharmaceuticals, Research and Development, Computational Molecular Design, Bayer AG, Wuppertal, Germany.
  • Alexander Hillisch
    Bayer AG , Drug Discovery, Chemical Research , 42096 Wuppertal , Germany.